Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06145308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 10, 2026 to Jul 10, 2028v5 Show 4 more changesShow less
    • Interventions: AR,darolutamide + goserelin+pertuzumab/trastuzumab (Drug), AR,darolutamide +goserelin +docetaxel (Drug), Albumin-paclitaxel + carboplatin +… to AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab (Drug), AR,AR antagonist +goserelin +docetaxel (Drug), Albumin-paclitaxel +…
    • Study description expanded, about 52 words
    • Site contacts updated at 2 of 2 sites
    • Study arms: 19 to 20
  2. Enrollment target: 10 to 39v4 Show 5 more changesShow less
    • Primary endpoints: 2 to 1
    • Study completion date: Jul 10, 2026 to Jul 10, 2028
    • Interventions: Apalolito vorellizumab group (Drug), ESG401 (Drug), HR-positive group (Drug), Homologous Recombination repair defect group (Drug), Ivoximab… to AR,darolutamide + goserelin+pertuzumab/trastuzumab (Drug), AR,darolutamide +goserelin +docetaxel (Drug), Albumin-paclitaxel + carboplatin +…
    • Study description shortened, about 6 words
    • Study arms: 12 to 19
  3. Enrollment target: 30 to 10v3 Show 4 more changesShow less
    • Start date changed from estimate of May 1, 2024 to Aug 15, 2023
    • Interventions: ESG401 (Drug), Vedolizumab (Drug), albumin paclitaxel with platinum (Drug), antiandrogen drug treatment (Drug), larotinib or enttraitinib… to Apalolito vorellizumab group (Drug), ESG401 (Drug), HR-positive group (Drug), Homologous Recombination repair defect group (Drug), Ivoximab…
    • Study description expanded, about 55 words
    • Study arms: 6 to 12
  4. Start date: Dec 1, 2023 to May 1, 2024
    • Interventions: SHR-A1921 (Drug), Vedolizumab (Drug), albumin paclitaxel with platinum (Drug), antiandrogen drug treatment (Drug), larotinib or… to ESG401 (Drug), Vedolizumab (Drug), albumin paclitaxel with platinum (Drug), antiandrogen drug treatment (Drug), larotinib or enttraitinib…
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
Trial Details
NCT Number NCT06145308
Lead Sponsor Peking Union Medical College
Collaborators: Peking University Hospital of Stomatology
Conditions
(from sponsor)		 Salivary Gland Carcinoma, Precision Therapy
Related terms Salivary Gland Neoplasms
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov